Title of Original Paper: Aberrant mannosylation profile and FTX/miR-342/ALG3-axis contribute to development of drug resistance in acute myeloid leukemia
Journal: Cell Death & Disease
Overview
This document serves as a formal retraction of the study published in June 2018 regarding the molecular mechanisms of drug resistance in acute myeloid leukemia (AML). The retraction was issued by the Editors-in-Chief of Cell Death & Disease following a detailed audit of the published data, which revealed significant irregularities that undermine the study's conclusions.
The Original Scientific Context
The original research sought to address a critical challenge in oncology: why certain leukemic cells survive chemotherapy. The authors focused on the "FTX/miR-342/ALG3-axis" and "aberrant mannosylation profiles" as potential drivers of drug resistance. By identifying these molecular pathways, the study aimed to provide a foundation for developing more effective AML treatments.
Identification of Data Duplication
The primary reason for this retraction is the discovery of data duplication within Figure 3f. During an editorial review, it was observed that experimental results representing two distinct drug treatments appeared to be identical. Specifically:
- Quadrant 10.95%: Representing the U/A (Vincristine) ALG3 shRNA panel.
- Quadrant 4.52%: Representing the T/A (Paclitaxel) ALG3 shRNA panel.
The Editors-in-Chief noted a replication between a group of data points across these two supposedly different experimental conditions. In scientific publishing, such replication is a major red flag, suggesting either extreme negligence in data handling or intentional manipulation.
Editorial Audit and Author Dissent
The retraction was the result of a visual and technical review of the published figures. Despite the clear evidence of duplication identified by the journal, the note explicitly states that all of the authors disagree with this retraction.
This highlights a significant tension between editorial authority and researcher dissent. The journal, acting as a steward of the scientific record, determined that the loss of confidence in the integrity of Figure 3 necessitated a full withdrawal of the paper to prevent the dissemination of unreliable data, regardless of the authors' stance.
Conclusion and Implications for Future Research
The formal invalidation of this study means that the proposed role of the FTX/miR-342/ALG3-axis in AML drug resistance remains unverified. While the underlying biological hypothesis may still be of interest to the scientific community, the specific evidence provided in the 2018 publication is no longer considered part of the reliable scientific record.
This retraction underscores the vital importance of research ethics and the necessity for journals to maintain rigorous oversight. For the scientific community, it serves as a reminder that the integrity of data is paramount; without it, even the most promising biological insights cannot be sustained.
Summary updated